Drug Profile

Nomacopan - Akari Therapeutics

Alternative Names: Coversin; EV 576; long-acting PAS-nomacopan; PAS-coversin; PAS-nomacopan; rEV 576; rVA576

Latest Information Update: 28 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Evolutec
Developer Akari Therapeutics; Evolutec; US Army Institute of Surgical Research
Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Antithrombotics; Antivirals; Eye disorder therapies; Recombinant proteins; Skin disorder therapies
Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy; Guillain-Barre syndrome; Bullous pemphigoid; Thrombotic microangiopathies
New Molecular Entity Yes
Available For Licensing Yes

Phase III Haemolytic uraemic syndrome
Phase I/II COVID-19 pneumonia; Keratoconjunctivitis
Preclinical Dry age-related macular degeneration
Suspended Thrombotic microangiopathy
No development reported Asthma; Guillain-Barre syndrome; Haemorrhagic shock; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Subarachnoid haemorrhage; Traumatic brain injuries; Uveitis; Wet age-related macular degeneration
Discontinued Autoimmune disorders; Bullous pemphigoid; Inflammation; Paroxysmal nocturnal haemoglobinuria

28 Jul 2025 No recent reports of development identified for preclinical development in Asthma in USA (SC, Injection)
28 Jul 2025 No recent reports of development identified for preclinical development in Haemorrhagic shock in USA
28 Jul 2025 No recent reports of development identified for preclinical development in Subarachnoid-haemorrhage in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com